Matthew F. Buas

Matthew F. Buas

PhD

Special Interests:

Cancer precursor lesions Genetic susceptibility Risk assessment Liquid biopsy Omics-based classifiers

Credentials

Positions

Roswell Park Comprehensive Cancer Center
  • Assistant Professor of Oncology
  • Assistant Member
  • Department of Cancer Prevention and Control
State University of New York at Buffalo
  • Research Assistant Professor
  • Department of Cancer Pathology and Prevention

Background

Education and Training:

  • PhD - Cell & Molecular Biology - University of Pennsylvania, Philadelphia, PA
  • MS - Epidemiology - University of Washington, Seattle, WA

Fellowship:

  • Post-doctoral Fellowship - Fred Hutchinson Cancer Research Center, Seattle, WA

Professional Memberships:

  • American Association for Cancer Research (AACR)
  • Barrett’s and Esophageal Adenocarcinoma Consortium (BEACON)

Research

Research Overview:

Dr. Buas’ primary research focus is the molecular/genetic epidemiology of esophageal adenocarcinoma (EA), and the development of novel approaches for cancer risk assessment, early diagnosis, and prevention. His active research includes basic etiologic studies of genetic susceptibility to EA and its precursor, Barrett’s esophagus (BE); applied biomarker discovery studies of circulating nucleic acids and metabolites linked to high-risk BE and early-stage EA; and integrative risk modeling studies aimed at combining genetic and non-genetic factors into robust predictors of absolute cancer risk. The long-term translational goal of this work is to synthesize improved clinical tools for enabling targeted prevention or timely interception of EA among at-risk individuals.

Contact Information:

Email: matthew.buas@roswellpark.org
Phone: 716-845-4754
Fax: 716-845-8487
Roswell Park Comprehensive Cancer Center
Elm and Carlton Streets
Carlton House A369
Buffalo, NY 14263


Publications

Full Publications list on PubMed

Dai JY, Wang X, Buas MF, Zhang C, Ma J, Wei B, Li Y, et al. (2018) Whole-genome sequencing of esophageal adenocarcinoma in Chinese patients reveals distinct mutational signatures and genomic alterations. Commun Biol. 1:174.

Buas MF, Gu H, Djukovic D, Zhu J, Reid BJ, Raftery D, Vaughan TL. (2017) Candidate serum metabolite biomarkers for differentiating gastroesophageal reflux disease, Barrett’s esophagus, and high-grade dysplasia/esophageal adenocarcinoma. Metabolomics, 13: 23.

Dong J, Buas MF, Gharahkhani P, Kendall BJ, Onstad L, Zhao S, Anderson LA, et al. (2017) Determining risk of Barrett’s esophagus and esophageal adenocarcinoma based on epidemiologic factors and genetic variants. Gastroenterology, 154(5):1273-1281.

Buas MF, He Q, Johnson LG, Onstad L, Levine DM, Thrift AP, Gharahkhani P, et al. (2016) Germline variation in inflammation-related pathways and risk of Barrett’s oesophagus and oesophageal adenocarcinoma. Gut, 66, 1739-1747. 

Gharahkhani P, Fitzgerald RC, Vaughan TL, Palles C, Gockel I, Tomlinson I, Buas MF, et al. (2016) Genome-wide association studies in oesophageal adenocarcinoma and Barrett's oesophagus: a large-scale meta-analysis. Lancet Oncol., 17, 1363-1373. 

Dai JY, Tapsoba Jde D, Buas MF; BEACON Consortium, Risch HA, Vaughan TL. (2016) Constrained Score Statistics Identify Genetic Variants Interacting with Multiple Risk Factors in Barrett's Esophagus. Am J Hum Genet., 99, 352-65.

Buas MF, Gu H, Djukovic D, Zhu J, Urban N, Raftery D, Li CI. (2016) Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors. Gynecol Oncol., 140, 138-44.

Buas MF, Levine DM, Makar KW, Utsugi H, Onstad L, Li X, Galipeau PC, et al. (2014) Integrative post-GWAS analysis of CDKN2A and TP53 SNPs and risk of esophageal adenocarcinoma. Carcinogenesis, 35, 2740-7.